New York, New York: The Tipline for 6 August 2020

“We’re in the midst of a pandemic” is an excuse that many of us have likely used over the past few months, but one generic drugmaker targeted in the Department of Justice’s price-fixing probe has cited the crisis as a reason for not settling with the agency. Teva Pharmaceuticals chief executive Kare Schultz told Bloomberg yesterday that his company would not sign a deferred prosecution agreement that might “cripple” its ability to supply drugs in the US during covid-19. Also in today’s Tipline, we have a proposed amendment to New York antitrust law that its sponsor says is intended to rein in titans of the technology business, plus the DOJ suing to block a hospital deal and a cartel defence lawyer moving firms.


Get unlimited access to all Global Competition Review content